NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis $3.05 -0.04 (-1.29%) Closing price 04:00 PM EasternExtended Trading$3.06 +0.02 (+0.49%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Voyager Therapeutics Stock (NASDAQ:VYGR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Voyager Therapeutics alerts:Sign Up Key Stats Today's Range$2.97▼$3.1150-Day Range$3.00▼$3.7352-Week Range$2.93▼$5.55Volume632,334 shsAverage Volume618,372 shsMarket Capitalization$187.94 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingModerate Buy Company Overview Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a clinical-stage biotechnology company focused on developing gene therapies and other medicines for diseases of the central nervous system. The company seeks to address neurological conditions by delivering therapeutic genetic material to specific cells in the brain and spinal cord. Voyager’s technology platform includes its TRACER AAV capsid discovery platform, which is designed to identify adeno-associated virus capsids that can cross the blood-brain barrier and enable broader distribution of gene therapies. Its research and development programs have targeted conditions including Huntington’s disease, Parkinson’s disease and other neurodegenerative disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, Voyager has advanced its programs through internal development and collaborations with pharmaceutical companies, including partnerships involving neurological gene therapy candidates. The company’s operations are primarily focused on biotechnology research, preclinical studies and clinical development, with activities conducted through its U.S. organization and strategic collaborators.AI Generated. May Contain Errors. Read More Voyager Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreVYGR MarketRank™: Voyager Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 307th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialVoyager Therapeutics has a consensus price target of $16.50, representing about 441.0% upside from its current price of $3.05.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Voyager Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.63) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.04% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 8.88.Change versus previous monthShort interest in Voyager Therapeutics has recently decreased by 4.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.39 News SentimentVoyager Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Voyager Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.70% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYGR Stock News HeadlinesVoyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comVoyager to Present at Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 16 at 1:00 AM | TradeSmith (Ad)TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)August 24, 2026 | theglobeandmail.comVoyager Reports Second Quarter 2026 Financial and Operating ResultsAugust 6, 2026 | finance.yahoo.comVoyager Therapeutics (VYGR) Receives a Rating Update from a Top AnalystAugust 4, 2026 | theglobeandmail.comVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026July 13, 2026 | markets.businessinsider.comVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026July 13, 2026 | globenewswire.comSee More Headlines VYGR Stock Analysis - Frequently Asked Questions How have VYGR shares performed this year? Voyager Therapeutics' stock was trading at $3.93 at the beginning of 2026. Since then, VYGR stock has decreased by 22.4% and is now trading at $3.05. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. The firm earned $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 57.92% and a negative net margin of 312.63%. When did Voyager Therapeutics IPO? Voyager Therapeutics (VYGR) raised $80 million in an IPO on Wednesday, November 11th 2015. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Who are Voyager Therapeutics' major shareholders? Top institutional investors of Voyager Therapeutics include BlackRock Inc. (8.56%), Opaleye Management Inc. (1.92%), Seven Fleet Capital Management LP (0.37%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include Alfred Sandrock, Robin Swartz, Nathan D Jorgensen, Peter P Pfreundschuh, Todd Alfred Carter and Sandell Jacquelyn Fahey. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today9/16/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VYGR's financial health is in the Yellow zone, according to TradeSmith. VYGR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VYGR CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees141Year Founded2014Price Target and Rating Average Price Target for Voyager Therapeutics$16.50 High Price Target$25.00 Low Price Target$8.00 Potential Upside/Downside+441.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.72 million Net Margins-312.63% Pretax Margin-312.26% Return on Equity-57.92% Return on Assets-45.00% Debt Debt-to-Equity RatioN/A Current Ratio7.51 Quick Ratio7.51 Sales & Book Value Annual Sales$40.37 million Price / Sales4.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book0.86Miscellaneous Outstanding Shares61,620,000Free Float53,793,000Market Cap$187.94 million OptionableOptionable Beta1.32 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VYGR) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
